AKBA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

56.18M

+20.82%

-0.015

-85%

59.33M

+3.47%

0.002

-102%

Estimates Revision

The market is revising No Change the revenue expectations for Akebia Therapeutics, Inc. (AKBA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -44.73%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-220%

In Past 3 Month

Stock Price

Go Down

-44.73%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast AKBA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKBA is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

H.C. Wainwright

Buy

downgrade

$8 -> $6

2025-10-30

Reason

H.C. Wainwright

Price Target

$8 -> $6

2025-10-30

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Akebia to $6 from $8 and keeps a Buy rating on the shares. The firm cites the announcement of the company not pursuing initiation of the Phase 3 VALOR trial or associated broad chronic kidney disease non-dialysis labeling for Vafeso for the target drop.

H.C. Wainwright

Matthew Caufield

initiated

2025-06-04

Reason

H.C. Wainwright

Matthew Caufield

Price Target

2025-06-04

initiated

Reason

H.C. Wainwright analyst Matthew Caufield assumed coverage of Akebia with a Buy rating and $8 price target. The company's approved product Vafseo indicated for the treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months, continues to gain uptake among dialysis organizations, the analyst tells investors in a research note. The firm believes the ongoing Vafseo launch can offset generic impact on the company's other approved product Auryxia, which has focused commercially on the hyperphosphatemia indication.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$7.5

2025-04-04

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$7.5

2025-04-04

Reiterates

Strong Buy

Reason

Jefferies

Roger Song

Strong Buy

Initiates

2025-04-01

Reason

Jefferies

Roger Song

Price Target

2025-04-01

Initiates

Strong Buy

Reason

Jefferies initiated coverage of Akebia with a Buy rating and $6 price target. Akebia is a commercial-stage biotech specializing in kidney disease, the analyst tells investors in a research note. The company's initial U.S. launch of Vafseo under the Transitional Drug Add-on Payment Adjustment is looking encouraging with potential durable sales post the TDAPA, the analyst tells investors in a research note. Jefferies says the company has a few early pipeline products with upside potential.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$7.5

2025-03-14

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$7.5

2025-03-14

Reiterates

Strong Buy

Reason

Piper Sandler

Allison Bratzel

Buy

Maintains

$4 → $6

2025-03-14

Reason

Piper Sandler

Allison Bratzel

Price Target

$4 → $6

2025-03-14

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Akebia to $6 from $4 and keeps an Overweight rating on the shares. The firm says it remains a buyer of Akebia shares following Q4 reporting, which included a look at Vafseo launch progress that Piper finds encouraging. The firm thinks the stock reaction is misplaced given its view that the Vafseo launch is poised to exceed expectations, with Q1 2025 revenue expected to be $10M-$11M, essentially doubling consensus and PSC estimates.

Valuation Metrics

The current forward P/E ratio for Akebia Therapeutics Inc (AKBA.O) is 79.49, compared to its 5-year average forward P/E of -2.54. For a more detailed relative valuation and DCF analysis to assess Akebia Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.54

Current PE

79.49

Overvalued PE

24.31

Undervalued PE

-29.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.42

Undervalued EV/EBITDA

-2.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.74

Current PS

1.60

Overvalued PS

2.76

Undervalued PS

0.72

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1879.81% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1879.81% over the last month.

Sold

Bought

AKBA News & Events

Events Timeline

No data

News

9.0

01-07NASDAQ.COM

Akebia Doses First Patient in Phase 2 Trial of Praliciguat for FSGS

9.0

01-06Globenewswire

Akebia Doses First Patient in Phase 2 Trial of Praliciguat for FSGS

5.0

01-05Globenewswire

Akebia Grants 197,900 Stock Options to New Employee

People Also Watch

Frequently Asked Questions

What is Akebia Therapeutics Inc (AKBA) stock price today?

The current price of AKBA is 1.52 USD — it has increased 2.01 % in the last trading day.

What is Akebia Therapeutics Inc (AKBA)'s business?

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.

What is the price predicton of AKBA Stock?

What is Akebia Therapeutics Inc (AKBA)'s revenue for the last quarter?

Akebia Therapeutics Inc revenue for the last quarter amounts to 58.77M USD, increased 57.01 % YoY.

What is Akebia Therapeutics Inc (AKBA)'s earnings per share (EPS) for the last quarter?

Akebia Therapeutics Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Akebia Therapeutics Inc (AKBA)'s fundamentals?

How many employees does Akebia Therapeutics Inc (AKBA). have?

Akebia Therapeutics Inc (AKBA) has 181 emplpoyees as of January 10 2026.

What is Akebia Therapeutics Inc (AKBA) market cap?

Today AKBA has the market capitalization of 403.36M USD.